Photo: Procedure team under monitors. Piron Guillaume / Unsplash
1. FDA approves Contego's Neuroguard IEP Direct system for carotid stenting with flow reversal and filter
The company calls the combination a new category of carotid revascularization, TCAR-IEP.
Contego Medical of Raleigh, N.C., said Nov. 10 that the FDA granted premarket approval for its Neuroguard IEP Direct System and 510(k) clearance for its Neuroguard IEP Embolic Protection System, which together provide flow reversal plus an integrated 40-micron distal filter through direct carotid access [1]. The stent delivery system combines stent, balloon and filter in one device, and the access sheath uses gravity-assisted flow reversal without venous access [1]. In the company's PERFORMANCE III pivotal study, the 30-day stroke rate was 0% in the intention-to-treat population, with no myocardial infarctions, cranial nerve injuries or stent thromboses and a 30-day major adverse event rate of 0.69% [1].
2. American Cancer Society now recommends routine PSA screening every two years for men 50 to 69
The 2010 guideline had called only for shared decision-making.
The American Cancer Society on Nov. 12 published an updated prostate cancer screening guideline in CA: A Cancer Journal for Clinicians that directly recommends PSA-based screening every two years for average-risk men ages 50 to 69, once clinicians ensure patients understand the benefits and harms [2]. Black men and non-Black men with a strong family history should be screened annually from 45 to 69, decisions for ages 70 to 74 should be individualized, and screening is not recommended at 75 or older [2]. A PSA of 3.0 ng/mL or higher should be repeated within two weeks to three months, and a confirmed elevation should prompt an offer of MRI or a validated biomarker before biopsy [2].
3. All of Us study: every one of nearly 100,000 participants carries pharmacogene variants
Nearly a quarter had been prescribed a drug known to interact with a variant they carry.
A University of Pittsburgh-led analysis of nearly 100,000 participants in the NIH All of Us Research Program, published Nov. 11 in Science Translational Medicine, found that every participant carried at least one variant in 16 genes that affect drug processing, with a median of nine variants per person [3]. 24.4% of participants had been prescribed a medication known to interact with a variant they carried, most commonly ondansetron, ibuprofen, omeprazole, pantoprazole and atorvastatin [3]. The researchers identified more than 17,000 previously undocumented variants and reported frequencies across several ancestry groups [3].
4. JAMA phase 1: oral actinide chelator HOPO 14-1 safe at single doses up to 7,500 mg
A pill for radioactive contamination that needs no IV line or trained personnel.
A Phase 1 nonrandomized trial of HOPO 14-1, an oral form of the chelator 3,4,3-LI(1,2-HOPO) intended for internal radioactive contamination, reported no serious adverse events or dose-limiting toxicities across seven dose levels from 100 mg to 7,500 mg in 42 healthy adults, according to a JAMA paper published online Nov. 11 [4]. Drug-related adverse events were mild to moderate and mainly gastrointestinal, including diarrhea (31%) and vomiting (14%), with absorption peaking within about one to two hours [4]. The authors describe it as the first shelf-stable, broad-spectrum actinide chelator in clinical development that does not require IV access [4].
Digest references
Contego Medical (PRWeb), "Contego Medical Receives FDA Approval for Neuroguard IEP Direct System for TCAR-IEP," Nov. 10, 2026. prweb.com
American Cancer Society, "American Cancer Society Updates Prostate Cancer Screening Guideline," Nov. 12, 2026. cancer.org
UPMC/University of Pittsburgh, "Everyone Carries Gene Variants That Affect How They Respond to Medications, Study Finds," Nov. 11, 2026. upmc.com
Goonewardena SN, et al., "HOPO 14-1, an Oral Actinide Chelator: A Phase 1 Nonrandomized Clinical Trial," JAMA, Nov. 11, 2026. jamanetwork.com